MedTrace Logo

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-09-17

No results posted yet for this study

Summary

Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes1. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.

Conditions

  • Diabetes
  • Liver Transplant; Complications
  • Kidney Transplant Failure

Interventions

DIAGNOSTIC_TEST

hemoglobin A1c

The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Mangesh Pagadala, MD · The Liver Institute Methodist Dallas Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-12
Primary Completion
2021-08-19
Completion
2021-08-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216303 on ClinicalTrials.gov